Open AccessProstate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer
Author(s) -
John R. Bright,
Rosina T. Lis,
Anson T. Ku,
Nicholas T. Terrigino,
Nichelle C. Whitlock,
Shana Y. Trostel,
Nicole V. Carrabba,
Stephanie Harmon,
Barış Türkbey,
Scott Wilkinson,
Adam G. Sowalsky
Publication year - 2022
Publication title -
the journal of urology/the journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.402
H-Index - 256
eISSN - 1527-3792
pISSN - 0022-5347
DOI - 10.1097/ju.0000000000002492
Subject(s) - medicine , prostate cancer , prostatectomy , glutamate carboxypeptidase ii , androgen deprivation therapy , prostate , immunostaining , enzalutamide , prostate specific antigen , pca3 , urology , biomarker , oncology , pathology , cancer , immunohistochemistry , androgen receptor , biochemistry , chemistry
Neoadjuvant intense androgen deprivation therapy (iADT) can exert a wide range of histological responses, which in turn are reflected in the final prostatectomy specimen. Accurate identification and measurement of residual tumor volumes are critical for tracking and stratifying patient outcomes.